Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $801

Benzinga Newsdesk www.benzinga.com Negative 51.4%

Neg 51.4% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $818 to $801.